source
- Leqembi posts $184M Q2 sales, best quarter since launch, Biogen lifts guidanceLeqembi, the anti-amyloid Alzheimer’s drug co-developed by Eisai and Biogen, generated $184 million in global sales in the second quarter, according to Biogen. The Q2 figure represents the stronge…
- FDA advisory panel advises against approving Capricor’s Duchenne cell therapy, deramiocelThe FDA Cellular, Tissue, and Gene Therapies Advisory Committee convened to evaluate deramiocel, a cell‑based treatment for Duchenne muscular dystrophy developed by Capricor Therapeutics. Capricor…